Nektar, Zelos to study inhaled Ostabolin-C for osteoporosis

By Lisa Kerner

Charlotte, N.C., Sept. 21 - Nektar Therapeutics and Zelos Therapeutics, Inc. began a phase 1 clinical trial of an inhaled powder formulation of Zelos' proprietary parathyroid hormone Ostabolin-C (cyclic PTH-(1-31)) for osteoporosis using Nektar's portable, pocket-sized inhaler.

The phase 1, single-center, randomized, double blind, placebo-controlled, escalating-dose study will enroll up to 56 healthy postmenopausal women to evaluate 28 days of dosing.

Primary study endpoints are the safety and tolerability of single and repeated doses of the inhaled bone formation agent.

A sub-study will also compare a single, subcutaneously injected dose of Ostabolin-C to a single dose of inhaled Ostabolin-C.

Zelos is a biopharmaceutical company based in West Conshohocken, Pa.

Nektar is a San Carlos, Calif., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.